Hemp and CBD Markets Projected to Become a Major Part of the Legal Cannabis Industry

Monday, October 2, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, October 2, 2017 /PRNewswire/ --

According to a report by

the Hemp Business Journal the CBDámarket is growing at 30 percent and will reach $2.1 billion in sales by 2020, and that $450 million of those sales will be from hemp based sources, and the
rest from cannabis sources. The report indicates that the total retail value of hemp products sold in the U.S. in 2016 wasá$688 million. As a result of successful legalization campaigns across several U.S. states and successful hemp cultivation pilot programs, sales of items like shelled seed, protein powder, soaps and lotions have continued to increase. In all, sales of Hemp CBD products boosted the industry to a five year 22% CAGR.áChineseinvestors.com, Inc. (OTC: CIIX), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Sativa, Inc. (OTC: CBDS), CV Sciences, Inc. (OTC: CVSI), Terra Tech Corp.á(OTC: TRTC)

A report by New Frontier Data points out the role of cannabis products for medical use in the pharmaceutical market. "The United States constitutes 35% of the global pharmaceutical market, the largest market in the world, and a major driver of the U.S. economy. It is one of many industries that will be impacted by the growth of the legal cannabis market and we are already starting to see that trend in legal medical states where use of key prescription drugs is down by 11%. If cannabis were to be adopted nationally, we would begin to see a trend of patients turning to medical cannabis as a substitute or complement to pharmaceuticals," said Giadha Aguirre De Carcer, CEO & Founder of New Frontier Data.

Chineseinvestors.com, Inc. (OTCQB: CIIX) just announced breaking news this morning that it has appointed Skin Care Industry veteran and Shanghai beauty influencer, Fannie (Chun Fang) Tang Marketing Director of its wholly owned foreign enterprise, CBD Biotechnology Co., Ltd. effective immediately. Ms. Tang will report directly to CBD Biotechnology's CEO, Summer Yun, and will be responsible for developing and implementing branding strategies for CBD Biotechnology's CBD Magic Hemp Series skin care line in China. With over 20 years' experience in the industry, Tang was highlighted in the book entitled Shanghai Beauty 26 as a leading influencer in Shanghai's beauty culture. Ms. Tang served as the CEO of L. D. Waxson Group's China Division until it was acquired in 2012 by India's third largest software services provider, Wipro Limited, for $144 million. L.D. Waxson, a leading skin care company with manufacturing facilities in China and Malaysia, and a strong footprint in Singapore, Malaysia, China, Taiwan, Hong Kong and Thailand, reported revenues of approximately $68m prior to its acquisition in 2012. It's portfolio of brands included the skin care lines Bioessence and Ginvera, and Ebene, a popular health care brand.

"With over twenty years' of marketing and branding experience in the skin care and cosmetics industry, I believe CBD Biotechnology is extremely fortunate to be working with Ms. Tang," says Yun. "Ms. Tang's concept of "Beauty Derives from Nature and Creation" aligns with CBD Biotechnology's vision to develop an innovative, natural skin care band. Moreover, Ms. Tang has proven success in the industry in this region. Through her efforts, we are confident that CBD Biotechnology will position itself to become a leader in China's skin care industry."

In September 2017, CBD Biotechnology completed the filing process with the China Food & Drug Administration for its first three products in the CBD Magic Hemp Series line, namely the CBDBIO TECH Brightening and Refreshing Moisturizer, the CBDBIO TECH Perfecting Shield Primer, and the CBDBIO TECH Peptide Collagen Solution, which are expected to be formally launched this month. The CBD Magic Hemp Series skin care line will be marketed through multiple sales channels, including online sales, app sales, and third party distribution relationships with online celebrities and market influencers.

"China can to be a complex business culture to navigate," says ChineseInvestors.com, Inc.'s CEO Warren Wang. As such, a company's management and leadership team is critical to its success. Ms. Tang is a proven marketing leader and beauty influencer in China. With Ms. Tang's expertise and a breakthrough hemp-infused skin care line, I believe we have the key elements for success in this market."

"I am honored to serve as the Marketing Director of CBD Biotechnology," says Tang. "Hemp extract, otherwise known as cannabidiol or CBD, is a powerful antioxidant and anti-inflammatory agent making it a perfect ingredient for skin care products. CBD Biotechnology will be among the first skin care companies in China to infuse its products with natural hemp extract making it a pioneer in this segment of the skin care industry. I believe CBD Biotechnology has a unique opportunity to take the lead in the Chinese market with its innovative skin care line."

Medical Marijuana, Inc. (OTC: MJNA) strives to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. On September 22nd, Medical Marijuana, Inc.,áportfolio company,áKannalife Sciences, Inc., a pharmaceutical and phyto-medical company, announced that former three time NFL Pro-Bowl and Kansas City Chiefs placekicker, Nick Lowery, has joined Kannalife corporate advisory board to lead the Company's initiative on speaking about chronic traumatic encephalopathy (CTE) and Kannalife's efforts to bring forth a clinically approved treatment for CTE. Kannalife Sciences holds the exclusive license from the federal government to commercialize a cannabinoid patent currently held by the U.S. Government and National Institutes of Health (NIH).

Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. OnáAugust 2nd, Cannabis Sativa, Inc. announced that the Company has acquiredáa controlling interest in PrestoCorp (a.k.a.áPrestoDoctor), an online telemedicine platform providing access to knowledgeableáphysicians for a safeáand confidential way to get a medical marijuana recommendationáusing secure video conferencing technology.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. Earlier in July, CV Sciences, Inc., provided an update on published outcomes of recent clinical researcháon pharmaceutical-grade cannabidiol (CBD) pointing to its therapeutic potential as a prescription drug. InáTheáNew England Journal of Medicineápublished on May 25, 2017, a clinical trial of pharmaceutical-grade CBD as an adjunct to standard anticonvulsive therapy sponsored by GW Pharmaceuticals in the control of a rare unremitting, drug-resistant seizure disorder, Dravet's syndrome, demonstrated a statistically significant reduction in the number of seizures in the patients receiving CBD versus placebo while both groups were maintained on standard anticonvulsants.

Terra Tech Corp.á(OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, on September 19th, announced that it has signed its second Craft Cultivator to grow the Company's proprietary high grade "IVXX" cannabis flowers and oils. The farm, Cultivar Inc., is located in Salinas, California and is approved for up to six acres (approximately 244,000 square feet) of cannabis cultivation, to be grown in high tech, climate-controlled greenhouses.

Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com á

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions, recommendations or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and PR services by chineseinvestors.com Inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with Chineseinvestors.com Inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, and quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

For further information: [email protected] +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook